These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35131437)

  • 1. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine.
    Muramatsu H; Lam K; Bajusz C; Laczkó D; Karikó K; Schreiner P; Martin A; Lutwyche P; Heyes J; Pardi N
    Mol Ther; 2022 May; 30(5):1941-1951. PubMed ID: 35131437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Optimization of a Freeze-Drying Process Achieving Enhanced Long-Term Stability and In Vivo Performance of Lyophilized mRNA-LNPs.
    Alejo T; Toro-Córdova A; Fernández L; Rivero A; Stoian AM; Pérez L; Navarro V; Martínez-Oliván J; de Miguel D
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thin-film freeze-drying of an influenza virus hemagglutinin mRNA vaccine in unilamellar lipid nanoparticles with blebs.
    Li Q; Shi R; Xu H; AboulFotouh K; Sung MMH; Oguin TH; Hayes M; Moon C; Dao HM; Ni H; Sahakijpijarn S; Cano C; Davenport GJ; Williams RO; Le Huray J; Cui Z; Weissman D
    J Control Release; 2024 Nov; 375():829-838. PubMed ID: 39293526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
    Vadovics M; Muramatsu H; Sárközy A; Pardi N
    Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
    Meulewaeter S; Nuytten G; Cheng MHY; De Smedt SC; Cullis PR; De Beer T; Lentacker I; Verbeke R
    J Control Release; 2023 May; 357():149-160. PubMed ID: 36958400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids.
    Lamoot A; Lammens J; De Lombaerde E; Zhong Z; Gontsarik M; Chen Y; De Beer TRM; De Geest BG
    Biomater Sci; 2023 Jun; 11(12):4327-4334. PubMed ID: 37073472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses.
    Pardi N; Carreño JM; O'Dell G; Tan J; Bajusz C; Muramatsu H; Rijnink W; Strohmeier S; Loganathan M; Bielak D; Sung MMH; Tam YK; Krammer F; McMahon M
    Nat Commun; 2022 Aug; 13(1):4677. PubMed ID: 35945226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.
    Gouma S; Furey C; Santos JJS; Parkhouse K; Weirick M; Muramatsu H; Pardi N; Fan SHY; Weissman D; Hensley SE
    J Virol; 2023 Jan; 97(1):e0172322. PubMed ID: 36533954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and lyophilization of mRNA-encapsulating lipid nanoparticles.
    Wang T; Yu T; Li W; Liu Q; Sung TC; Higuchi A
    Int J Pharm; 2024 Sep; 662():124514. PubMed ID: 39067550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines.
    Kim B; Hosn RR; Remba T; Yun D; Li N; Abraham W; Melo MB; Cortes M; Li B; Zhang Y; Dong Y; Irvine DJ
    J Control Release; 2023 Jan; 353():241-253. PubMed ID: 36414195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.
    Shi R; Liu X; Wang Y; Pan M; Wang S; Shi L; Ni B
    Hum Vaccin Immunother; 2024 Dec; 20(1):2342592. PubMed ID: 38714327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses.
    Wan J; Wang Z; Wang L; Wu L; Zhang C; Zhou M; Fu ZF; Zhao L
    mBio; 2024 Jan; 15(1):e0177523. PubMed ID: 38078742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings.
    Fan Y; Rigas D; Kim LJ; Chang FP; Zang N; McKee K; Kemball CC; Yu Z; Winkler P; Su WC; Jessen P; Hura GL; Chen T; Koenig SG; Nagapudi K; Leung D; Yen CW
    J Control Release; 2024 Sep; 373():727-737. PubMed ID: 39059500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.
    Ripoll M; Bernard MC; Vaure C; Bazin E; Commandeur S; Perkov V; Lemdani K; Nicolaï MC; Bonifassi P; Kichler A; Frisch B; Haensler J
    Biomaterials; 2022 Jul; 286():121570. PubMed ID: 35576809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses.
    McMahon M; O'Dell G; Tan J; Sárközy A; Vadovics M; Carreño JM; Puente-Massaguer E; Muramatsu H; Bajusz C; Rijnink W; Beattie M; Tam YK; Kirkpatrick Roubidoux E; Francisco I; Strohmeier S; Kanekiyo M; Graham BS; Krammer F; Pardi N
    Proc Natl Acad Sci U S A; 2022 Nov; 119(45):e2206333119. PubMed ID: 36322769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.
    Freyn AW; Ramos da Silva J; Rosado VC; Bliss CM; Pine M; Mui BL; Tam YK; Madden TD; de Souza Ferreira LC; Weissman D; Krammer F; Coughlan L; Palese P; Pardi N; Nachbagauer R
    Mol Ther; 2020 Jul; 28(7):1569-1584. PubMed ID: 32359470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
    Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
    Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA.
    Barbieri BD; Peeler DJ; Samnuan K; Day S; Hu K; Sallah HJ; Tregoning JS; McKay PF; Shattock RJ
    J Control Release; 2024 Oct; 374():280-292. PubMed ID: 39142355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
    Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
    Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice.
    Zhuang X; Chen L; Yang S; Xia S; Xu Z; Zhang T; Zeng B; Yu T; Yu N; Wang W; Lu H; Tian M; Jin N
    Front Immunol; 2022; 13():836274. PubMed ID: 35711431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.